Chris Gibson

Chris is CEO and co-founder of Recursion Pharmaceuticals. He completed his Ph.D. in bioengineering at the University of Utah in the Fall of 2013 before taking a leave of absence from medical school to found and grow Recursion. He developed the core technology underlying this venture while in the lab of Dr. Dean Li.

Chris comes from a family of entrepreneurs, is a graduate of Rice University with degrees in bioengineering and managerial studies and has completed an intense course in entrepreneurship at Stanford GSB. Chris is also a Board Member of CureHHT, a patient advocacy group for Hereditary Hemorrhagic Telangiectasia, and Recursion’s first spin-co, CereXis, Inc. Chris enjoys cycling on both the road and the trails that cut through Utah’s great wilderness, as well as spending precious time with his family.